benefits of tirzepatide over semaglutide & are transforming diabetes & obesity management. These GLP-1 receptor agonists offer from glycemic control to weight loss and cardiovascular risk reduction, emphasizing their broad impact. Read more from Comparative safety and side effects

Not to sound like a broken record, but: It depends

Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years

Pramlintide as an adjunct therapy in patients with type 2 diabetes

What happens when you take these drugs When someone starts a GLP-1 medication, the changes are often immediate